The use of a nutritional formula with slow release carbohydrates can reduce the frequency and the depth of the hypoglycemic events in subjects with type 1 diabetes mellitus

  • Patrizio Tatti
  • Leonardo Masselli
  • Patrizia di Mauro
  • Giuseppe Pipicelli
  • Felice Strollo
Original Article


Hypoglycemia is a frequent and often dramatic event in subjects with type 1 diabetes. It is also probable that an unrecognized nocturnal hypoglycemia may cause a marked variability of the fasting blood glucose. We used a nutritional formula with slow release carbohydrates represented by modified maltodextrins to reduce the risk of these events in 14 type 1 diabetic subjects. The continuous subcutaneous monitoring of interstitial glucose demonstrated a marked reduction in the number and depth of the hypoglycemic episodes throughout the 48 h when the formula was used versus the preceding 48 h.


Hypoglycemia Hypoglycemia prevention Glucose variability 


Conflict of interest



  1. 1.
    Pollak MF et al (2010) Patient reported tolerability issues with oral antidiabetic agents: association with adherence, treatment satisfaction and health related quality of life. Diabetes Res Clin Pract 87:204–210CrossRefGoogle Scholar
  2. 2.
    Cryer PE et al (2003) Hypoglycemia in diabetes. Diabetes Care 26(6):1902CrossRefGoogle Scholar
  3. 3.
    ADA (2010) Standards of medical care in diabetes mellitus. Diabetes Care 33(Suppl 1):S11–S61Google Scholar
  4. 4.
    American Association of Clinical Endocrinologists (2007) Medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 13(Suppl 1):1–68Google Scholar
  5. 5.
    Ryden L et al (2007) Guidelines on diabetes, prediabetes and Cardiovascular diseases: executive summary. The Task force on diabetes and cardiovascular disease of the European Society for Cardiology (ESC and the European Association for the Study of Diabetes (EASD). Eur Heart J. doi: 10.109/eurheartl/ehl261
  6. 6.
    Holstein A et al (2003) Risk of hypoglycemia with oral antidiabetic agents. Exp Clin Endocrinol Diabetes 111:405–414CrossRefGoogle Scholar
  7. 7.
    Jermandy G, for the Hungarian RECAP group et al (2008) Outcomes of adding a second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary. Health Qual Life Outcomes. 6:88. doi  10.1186/477-7525-6-88
  8. 8.
    Greco D et al (2004) Drug induced severe hypoglycemia in type 2 diabetic patients aged 80 years or older. Diabetes Nutr Metab 17:23–26Google Scholar
  9. 9.
    Risso A et al (2001) Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab 281:E924–E930Google Scholar
  10. 10.
    Cranston I et al (1994) Restoration of hypoglycemia unawareness in patients with long duration insulin-dependent diabetes mellitus. Lancet 344:283–287CrossRefGoogle Scholar
  11. 11.
    Dagogo-Jack S et al (1994) Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes 43:1426–1434CrossRefGoogle Scholar
  12. 12.
    Fanelli CG et al (1994) Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycemia following institution of rational intensive therapy in IDDM. Diabetologia 37:1265–1276CrossRefGoogle Scholar
  13. 13.
    Kilpatrick ES et al (2007) Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia 50:2553–2561CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Patrizio Tatti
    • 1
  • Leonardo Masselli
    • 1
  • Patrizia di Mauro
    • 1
  • Giuseppe Pipicelli
    • 2
  • Felice Strollo
    • 3
  1. 1.UOCA di Endocrinologia e DiabetologiaRomeItaly
  2. 2.UOC di Diabetologia e MetabolismoCatanzaro (CZ)Italy
  3. 3.UOC di EndocrinologiaIstituto INRCARomeItaly

Personalised recommendations